FHTX R&D to Revenue
Foghorn Therapeutics Inc · R&D to Revenue
FHTX R&D to Revenue
Latest reported115.25%period ending
FHTX Quarterly R&D/Revenue (0.00% → 115.25%)
Latest values, visible window
High-resolution chart · PNG
FHTX r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 115.2501% | |
| 558.8919% | |
| 248.1453% | |
| 245.333% | |
| 276.4589% | |
| 363.3401% | |
| 718.0672% | |
| 316.2013% | |
| 345.4849% | |
| 505.6238% | |
| 404.8015% | |
| 150.1945% | |
| 522.379% | |
| 564.7956% | |
| 674.1874% | |
| 405.909% | |
| 578.4855% | |
| 625.2041% | |
| 3,150.4909% | |
| 49,985.3659% | |
| 6,681.7204% | |
| 6,547.5524% | |
| 6,337.8486% | |
| 9,001.676% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |